CK0801
Phase 1Biologic
CK0801 is one of 11 biologic programs targeting Bone Marrow Failure Syndrome. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Bone Marrow Failure Syndrome
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Approved
Atgam
NovartisPhase 3
Fludara
SanofiPhase 3
Busulfex
Akero TherapeuticsPhase 3
Fludarabine Monophosphate
SSt. Petersburg State Pavlov Medical University
Phase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 2
Tepadina
Alnylam PharmaceuticalsPhase 1
Gleevec
NovartisPhase 1
Therapeutic Allogeneic Lymphocytes
EEastern Cooperative Oncology Group
Phase 1
Granulocyte Colony-Stimulating Factor
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CK0801. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- CCellenkos, Inc.